AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12074764 — intervention group
Group type: EXPERIMENTAL
Intervention: Zevalin (ibritumomab tiuxetan)
Number of subjects: 143
Study 12074764 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 143
Study 7668872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with MMC 12 mg/m2 on the day of operation, followed by 6 mg/m2 every two months for 6 times, and FT 800 mg/body/day for one year.
Number of subjects: 357
Study 7668872 — intervention group
Group type: COMPARATOR
Intervention: Control group with operation only.
Number of subjects: 357
Study 7668872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in colon cancer cases with highly positive lymph node metastasis and positive lymphatic vessel invasion.
Number of subjects: 357
Study 7668872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in rectal cancer cases, specifically Dukes C cases.
Number of subjects: 357
Study 7668872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in rectal cancer cases with local recurrence, specifically Dukes C and cases of relative curative resection.
Number of subjects: 357
Study 2913466 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal substitutional therapy
Number of subjects: 128
Study 2913466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 1570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordaron
Number of subjects: 55
Study 1570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 1570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonachlasine
Number of subjects: 55
Study 30873561 — intervention group
Group type: EXPERIMENTAL
Intervention: HAY group (forage included)
Number of subjects: 16
Study 30873561 — intervention group
Group type: COMPARATOR
Intervention: CON group (no forage)
Number of subjects: 16
Study 28880380 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP-825 (22 mg sumatriptan nasal powder)
Number of subjects: 259
Study 28880380 — intervention group
Group type: COMPARATOR
Intervention: Oral sumatriptan (100 mg tablets)
Number of subjects: 259
Study 25572140 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg IV bolus injection (10 s)
Number of subjects: 20
Study 25572140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride) IV administration
Number of subjects: 20
Study 23411098 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mm clear corneal incision (CCI) system (Group 1, Stellaris system)
Number of subjects: 100
Study 23411098 — intervention group
Group type: COMPARATOR
Intervention: 2.2 mm CCI system (Group 2, Intrepid Infiniti system)
Number of subjects: 100
Study 23411098 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day postoperative evaluation
Number of subjects: 100
Study 23411098 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week postoperative evaluation
Number of subjects: 100
Study 23411098 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months postoperative evaluation
Number of subjects: 100
Study 20131073 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity diode laser adjunct to root scaling and planing
Number of subjects: 27
Study 20131073 — intervention group
Group type: COMPARATOR
Intervention: Root scaling and planing (Control)
Number of subjects: 27
Study 19474649 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident HSV‐2 infection
Number of subjects: 6396
Study 19474649 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic HSV‐2 infection
Number of subjects: 6396
Study 19474649 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital ulcer disease
Number of subjects: 6396
Study 19474649 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral discharge
Number of subjects: 6396
Study 19474649 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital washing after intercourse
Number of subjects: 6396
Study 19474649 — intervention group
Group type: EXPERIMENTAL
Intervention: Being unmarried
Number of subjects: 6396
Study 19474649 — intervention group
Group type: EXPERIMENTAL
Intervention: Being uncircumcised
Number of subjects: 6396
Study 19474649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIV and HSV‐2 acquisition
Number of subjects: 6396
Study 17893003 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 2948
Study 15328329 — intervention group
Group type: EXPERIMENTAL
Intervention: List of Head Start telephone contacts and a computer‐generated packet containing a physician referral letter
Number of subjects: 246
Study 15328329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 246
Study 11165589 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-aortic drainage
Number of subjects: 80
Study 11165589 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 80
Study 9973801 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (1 mg/kg/day)
Number of subjects: 16
Study 9973801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8152760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipivefrin
Number of subjects: 33
Study 8152760 — intervention group
Group type: COMPARATOR
Intervention: Naphazoline
Number of subjects: 33
Study 8152760 — intervention group
Group type: COMPARATOR
Intervention: NaCl solution (0.9%)
Number of subjects: 33
Study 8152760 — intervention group
Group type: COMPARATOR
Intervention: Dipivefrin, naphazoline, and 0.9% NaCl
Number of subjects: 33
Study 3370632 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin A per week for 6 months
Number of subjects: 54
Study 3370632 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 54
Study 338255 — intervention group
Group type: EXPERIMENTAL
Intervention: feprazone (600 mg/day)
Number of subjects: 21
Study 338255 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen (1200 mg/day)
Number of subjects: 21
Study 31941539 — intervention group
Group type: EXPERIMENTAL
Intervention: OWise Breast Cancer mobile application for self‐monitoring symptoms and managing care
Number of subjects: 0
Study 31941539 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus OWise
Number of subjects: 0
Study 31941539 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 30515992 — intervention group
Group type: EXPERIMENTAL
Intervention: RePace
Number of subjects: 28
Study 30515992 — intervention group
Group type: COMPARATOR
Intervention: DUC
Number of subjects: 28
Study 28619778 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating objectively recorded adherence from the Inhaler Compliance Assessment (INCA) device and lung function into clinical decision making.
Number of subjects: 0
Study 28619778 — intervention group
Group type: COMPARATOR
Intervention: Standard inhaler and adherence education (Control group).
Number of subjects: 0
Study 28619778 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group using adherence data and clinical decision protocol.
Number of subjects: 0
Study 28619778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of the INCA device intervention.
Number of subjects: 0
Study 26431977 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT (100 μg mL(‐1) TBO followed by 94J cm(‐2) LED irradiation)
Number of subjects: 45
Study 26431977 — intervention group
Group type: COMPARATOR
Intervention: Non-PACT control
Number of subjects: 45
Study 23512869 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Intake Monitoring Application (DIMA)
Number of subjects: 44
Study 23512869 — intervention group
Group type: COMPARATOR
Intervention: Daily Activity Monitor Application (DAMA)
Number of subjects: 44
Study 23258380 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cold‐light bleaching procedure
Number of subjects: 12
Study 23258380 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching agent
Number of subjects: 12
Study 23258380 — intervention group
Group type: COMPARATOR
Intervention: Peroxide‐free bleaching agent
Number of subjects: 12
Study 23258380 — intervention group
Group type: COMPARATOR
Intervention: Cold‐light
Number of subjects: 12
Study 20390807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parent-child/family therapy treatment
Number of subjects: 48
Study 20390807 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral individual child treatments
Number of subjects: 48
Study 20390807 — intervention group
Group type: COMPARATOR
Intervention: Individual child treatments
Number of subjects: 48
Study 17712672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic treatment with AM‐111 at a concentration of 0.4 mg/ml or 2 mg/ml
Number of subjects: 11
Study 17712672 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 11
Study 16332650 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary fiber intake (highest quintile)
Number of subjects: 5961
Study 16332650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsoluble dietary fiber intake (highest quintile)
Number of subjects: 5961
Study 16332650 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble dietary fiber intake
Number of subjects: 5961
Study 16332650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber from cereals
Number of subjects: 5961
Study 16332650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber from vegetables
Number of subjects: 5961
Study 16332650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber from fruit
Number of subjects: 5961
Study 16332650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber from dried fruit or nuts and seeds
Number of subjects: 5961
Study 16332650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber from pulses
Number of subjects: 5961
Study 12389003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine tablets (10 mg)
Number of subjects: 64
Study 12389003 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine capsules (10 mg)
Number of subjects: 64
Study 9665096 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (4 g/d)
Number of subjects: 224
Study 9665096 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (4 g/d)
Number of subjects: 224
Study 9665096 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (4 g/d, control)
Number of subjects: 224
Study 9665096 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA and EPA (marine oil groups)
Number of subjects: 224
Study 8073825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacalcitol ointment (2 micrograms/g)
Number of subjects: 0
Study 8073825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2684111 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lip sclerectomies
Number of subjects: 80
Study 2684111 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomies
Number of subjects: 80
Study 818720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (320 mg per day, 160 mg twice daily)
Number of subjects: 30
Study 30189048 — intervention group
Group type: EXPERIMENTAL
Intervention: Myasthenia gravis cohort
Number of subjects: 6478
Study 30189048 — intervention group
Group type: EXPERIMENTAL
Intervention: Myasthenia gravis cohort who underwent thymectomy
Number of subjects: 6478
Study 28929816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoair® 125 Aerosol, 2 inhalations twice daily for 8 weeks
Number of subjects: 68
Study 28929816 — intervention group
Group type: COMPARATOR
Intervention: Adoair® 250 Diskus®, 1 inhalation twice daily for 8 weeks
Number of subjects: 68
Study 28929816 — intervention group
Group type: COMPARATOR
Intervention: Both devices (DPI and pMDI)
Number of subjects: 68
Study 25989968 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope (GVL)
Number of subjects: 26
Study 23368820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (150,000 U by i.v. drip infusion for 2 hours)
Number of subjects: 44
Study 23368820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23368820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 44
Study 21629015 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime prevalence of psychiatric disorders
Number of subjects: 1054
Study 21629015 — intervention group
Group type: EXPERIMENTAL
Intervention: Point prevalence of psychiatric disorders
Number of subjects: 1054
Study 21629015 — intervention group
Group type: EXPERIMENTAL
Intervention: Common psychiatric disorders identified
Number of subjects: 1054
Study 21629015 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity of psychiatric disorders
Number of subjects: 1054
Study 21629015 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of mental illness
Number of subjects: 1054
Study 19465485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose octreotide (60 mg/28 days)
Number of subjects: 26
Study 19465485 — intervention group
Group type: COMPARATOR
Intervention: High-frequency octreotide (30 mg/21 days)
Number of subjects: 26
Study 16981257 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (peginterferon-alpha-2a 180 mug/wk, ribavirin 800-1000 mg/d, amantadine 200 mg/d for 48 wk)
Number of subjects: 196
Study 16981257 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon-alpha-2a (6 MU/d for 4 wk, 3 MU/d for 20 wk, and 3 MU tiw for 24 wk) plus ribavirin (800-1000 mg/d) and amantadine (200 mg/d for 48 wk)
Number of subjects: 196
Study 16981257 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 196
Study 12928466 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional risk factors (cigarette smoking, diabetes, hyperlipidemia, hypertension)
Number of subjects: 122458
Study 12928466 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional risk factors
Number of subjects: 122458
Study 12928466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 122458
Study 10950441 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 38
Study 10950441 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 9165204 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber tray
Number of subjects: 1670
Study 9165204 — intervention group
Group type: COMPARATOR
Intervention: Screening tray
Number of subjects: 1670
Study 8142675 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (200 mg orally, 2 or 4 times daily) + Amphotericin B (200 mg orally, 4 times daily)
Number of subjects: 106
Study 8142675 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B only
Number of subjects: 106
Study 2878598 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily bevantolol (200 mg)
Number of subjects: 21
Study 2878598 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily bevantolol (200 mg)
Number of subjects: 21
Study 30175789 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosylceramide (GlcCer) derived from torula yeast (Candida utilis), 1.8 mg/d for 4 weeks
Number of subjects: 17
Study 30175789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30175789 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosylceramide (GlcCer) derived from torula yeast (Candida utilis)
Number of subjects: 17
Study 26198617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapyloric BTX‐A injection (group I)
Number of subjects: 115
Study 26198617 — intervention group
Group type: COMPARATOR
Intervention: No injection (group II)
Number of subjects: 115
Study 26198617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 115
Study 25099318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticoids (1 mg/kg daily, decreasing by one-third per week for 3 weeks)
Number of subjects: 61
Study 25099318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 22232457 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling Malaria Indicator Surveys (rMIS)
Number of subjects: 50
Study 20135139 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 68
Study 20135139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab administered 7 days before vitrectomy
Number of subjects: 68
Study 20135139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab administered 20 days before vitrectomy
Number of subjects: 68
Study 18055815 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 50
Study 18055815 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone
Number of subjects: 50
Study 15811091 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-MOP 0.01% gel plus UVA
Number of subjects: 22
Study 15811091 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus UVA
Number of subjects: 22
Study 11916547 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m²), Vinorelbine (25 mg/m²), Cisplatin (75 mg/m²) every 3 weeks
Number of subjects: 31
Study 11916547 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity profile of the treatment
Number of subjects: 31
Study 10216806 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (200 mg b.i.d. to 300 mg b.i.d.)
Number of subjects: 528
Study 10216806 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5 mg o.d. to 20 mg o.d.)
Number of subjects: 528
Study 10216806 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan + Hydrochlorothiazide (HCTZ) (12.5‐25 mg o.d.)
Number of subjects: 528
Study 10216806 — intervention group
Group type: COMPARATOR
Intervention: Enalapril + HCTZ (if required)
Number of subjects: 528
Study 7602359 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment: craniospinal radiotherapy (RT) followed by eight cycles of 1‐(2‐chloro‐ethyl)‐3‐cyclohexylnitrosourea (CCNU), vincristine (VCR), and prednisone
Number of subjects: 55
Study 7602359 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-in-1 chemotherapy followed by RT and then eight additional cycles of 8-in-1
Number of subjects: 55
Study 7602359 — intervention group
Group type: EXPERIMENTAL
Intervention: M0 stage
Number of subjects: 55
Study 7602359 — intervention group
Group type: EXPERIMENTAL
Intervention: M1-4 stage
Number of subjects: 55
Study 7602359 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 1.5 to 2 years
Number of subjects: 55
Study 7602359 — intervention group
Group type: EXPERIMENTAL
Intervention: >= 3 years
Number of subjects: 55
Study 2228353 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-glucose (G) ingestion
Number of subjects: 10
Study 2228353 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-fructose (F) ingestion
Number of subjects: 10
Study 2228353 — intervention group
Group type: COMPARATOR
Intervention: Water only (W) ingestion
Number of subjects: 10
Study 313330 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 7
Study 313330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 7
Study 313330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30269889 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM-guided algorithm
Number of subjects: 355
Study 30269889 — intervention group
Group type: COMPARATOR
Intervention: Classical-guided algorithm
Number of subjects: 355
Study 28351830 — intervention group
Group type: EXPERIMENTAL
Intervention: I-DECIDE, a Web-based healthy relationship tool and safety decision aid
Number of subjects: 0
Study 28351830 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26177812 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Treatment (hygiene and foot-care intervention)
Number of subjects: 680
Study 26177812 — intervention group
Group type: COMPARATOR
Intervention: Delayed Treatment (control group)
Number of subjects: 680
Study 26177812 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Number of subjects: 680
Study 23636185 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine)
Number of subjects: 131
Study 23636185 — intervention group
Group type: COMPARATOR
Intervention: Anesthetic injection alone (2 mL 1% lignocaine)
Number of subjects: 131
Study 21289020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (0.4 mg/0.1 ml)
Number of subjects: 62
Study 21289020 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal placebo
Number of subjects: 62
Study 21289020 — intervention group
Group type: EXPERIMENTAL
Intervention: Post cataract steroid subgroup (Intravitreal dexamethasone)
Number of subjects: 62
Study 19661193 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP levels
Number of subjects: 2312
Study 19661193 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fibrinogen levels
Number of subjects: 2312
Study 19661193 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma viscosity
Number of subjects: 2312
Study 15918296 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with high dose of allergenic extract (Group 2)
Number of subjects: 75
Study 15918296 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with low dose of allergenic extract (Group 1)
Number of subjects: 75
Study 15918296 — intervention group
Group type: COMPARATOR
Intervention: Control group (non SIT-treated patients)
Number of subjects: 75
Study 12816681 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 67
Study 12816681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 11783172 — intervention group
Group type: EXPERIMENTAL
Intervention: Xialian Yiyou Capsule (XLYYC)
Number of subjects: 226
Study 11783172 — intervention group
Group type: COMPARATOR
Intervention: Lizhu Dele Capsule (Control)
Number of subjects: 226
Study 8605463 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self management
Number of subjects: 115
Study 8605463 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 115
Study 1756252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human factor VIII (BAY w 6240) administered prophylactically three times a week for 4 weeks
Number of subjects: 5
Study 1756252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human factor VIII (BAY w 6240)
Number of subjects: 5
Study 1756252 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived factor VIII preparation (pdFVIII)
Number of subjects: 5